We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Two Genes Predict Survival in Early Lung Cancer

By Biotechdaily staff writers
Posted on 08 Mar 2007
Among patients with early-stage non–small-cell lung cancer (NSCLC) undergoing potentially curative surgery, the coexpression of 2 gene proteins identifies a subgroup with an excellent prognosis.

Investigators from the Lee Moffitt Cancer Center (Tampa, FL, USA) reported in the February 22, 2007, issue of the New England Journal of Medicine that the two genes, both involved in DNA synthesis and repair, are the regulatory subunit of ribonucleotide reductase (RRM1) and the excision repair cross-complementation group 1 (ERCC1). More...
About 30% of the patients investigated (55 of 184) had high levels of both gene markers, and clinical records showed that they had excellent outcomes.

Patients who have high expression of these two gene proteins do not need to receive adjuvant chemotherapy, as almost all of these patients are truly cured by surgery, said senior author Gerold Bepler, M.D., Ph.D.

Adjuvant chemotherapy is given to most patients with completely resected lung cancer, usually immediately after surgery, Dr. Bepler explained. The aim is to prevent disease recurrence, which occurs in about half the patients. However, this treatment has resulted in an approximately 10% improvement in patients' survival, meaning that many patients get chemotherapy after surgery without getting a benefit, and some will even be harmed by this.

For their study, Dr. Bepler and colleagues developed a process for automative quantitative determination of the RRM1 protein in routinely processed histologic specimens. They also measured expression of ERCC1 and another protein, the phosphatase and tensin homolog (PTEN), but found that this third marker was not correlated with survival.

The researchers commented that analysis of RRM1 has been technically difficult in the past, but the system they developed allows gene-expression analysis of both RRM1 and ERCC1 that is objective, reliable, and reproducible.

The same 2 gene markers have previously been shown to predict which patients with advanced NSCLC have a poor response to chemotherapy with gemcitabine and platinum compounds.

RRM1 and ERCC1 are important in controlling the 'integrity' of the DNA during cell doubling, Dr. Bepler explained. We already know that chemo does not work well in patients with high expression of both genes, because chemo works by causing DNA damage, which is fixed by these genes. Hence, patients with low levels of these genes have a more aggressive cancer and benefit most from chemotherapy, he said.


Related Links:
Lee Moffitt Cancer Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.